Third Pole Therapeutics, Inc.
Third Pole Therapeutics develops and delivers critical life-sustaining cardio-pulmonary therapies. Warren Zapol, M.D., Third Pole’s founder, invented the first use for inhaled nitric oxide (iNO) for the treatment of hypoxic respiratory failure in new-born infants (blue babies). Since then, in addition to blue babies, hundreds of thousands of pediatric and adult patients experiencing elevated pulmonary pressure, inflammation and poor oxygenation during and after heart surgery have been treated with inhaled nitric oxide, creating a $600 million inhaled nitric oxide market, concentrated in large hospitals, and developed markets.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical / Health Care
- Market Focus:
- Globally (various continents)
- Employees:
- 11-100
About Us
Two decades later, Third Pole has successfully created a scalable technology that delivers nitric oxide for inhalation, instantly, on-demand, and in unlimited quantities. Third Pole’s technology solves the cost and logistical hurdles which have prevented widespread iNO use in various markets in the U.S. and abroad that lacked the training and infrastructure required to transport, maintain, return, and refill large cylinders of compressed gas safely. Third Pole’s two novel platforms include eNOfit™ a miniaturized wearable device for home and travel and eNOcare™, a lightweight portable in-hospital device. Both make iNO by combining electricity and the air we breathe, creating a “make it and take it” therapy, free from the hazards of compressed gas storage. These broadly patented, versatile platforms have the potential to rapidly capture the entire existing tank-based market and expand beyond current indications to treat interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, and life threatening, viral, and bacterial infections.
Our History
The core technology of the device is based on innovations developed by the head of Third Pole’s Scientific Advisory Board, Professor Warren Zapol at Harvard’s Massachusetts General Hospital. Professor Zapol was flying from Boston to Los Angeles to visit a colleague, who won the Nobel Prize for the discovery of NO’s biological role, when lightning inspired his pioneering idea to use electric current to produce NO. After meticulous follow-up work in his lab, and careful testing over several years, Professor Zapol and the Third Pole team developed an investigational device that uses proprietary technology to produce pure NO for inhalation on-demand from air, enabling bedside and portable therapeutic use.
Policies
Quality Policy
Third Pole is committed to the design, development, manufacture, distribution, installation, service and repair of electric nitric oxide (eNO) generation and delivery systems and related accessories for inhalation therapies including hospital, transport and home care use. We actively engage all kinds of users to understand their needs and support them as they build, use and service our products.
Third Pole is committed to ensuring the Quality Management System and Quality Objectives maintain their effectiveness through regular review and are compliant with ISO 13485:2016 as well as applicable laws and regulations related to our products.
Conflict of Interest Policy
Third Pole’s conflict of interest policy as required by our NIH funded research is available for download.